Portfolio

Product
Orphacol®

Cholic acid

Indication

Treatment of inborn errors in primary bile synthesis due to deficiencies in:

  • 3β-hydroxy-Δ5-C27-steroid oxydoreductase
  • Δ4-3-oxydosteroid-5β reductase
in infants, children and adolescents aged 1 month to 18 years and adults

Therapeutic area

Inherited metabolic disorders

Neofordex ®


Dexamethasone

Indication

In adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products

Therapeutic area

Onco-haematology

Product Indication Therapeutic area
Orphacol®

Cholic acid

Treatment of inborn errors in primary bile synthesis due to deficiencies in:

  • 3β-hydroxy-Δ5-C27-steroid oxydoreductase
  • Δ4-3-oxydosteroid-5β reductase
in infants, children and adolescents aged 1 month to 18 years and adults

Inherited metabolic disorders

Neofordex ®


Dexamethasone

In adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products

Onco-haematology

Orphacol ®
Cholic acid

  • Capsule containing 50 mg of cholic acid in packs of 30
  • Capsule containing 250 mg of cholic acid in packs of 30
Treatment of inborn errors in primary bile acid synthesis due to deficiencies in:
  • 3β-hydroxy-Δ5-C27-steroid oxidoreductase
  • Δ4-3-oxosteroid-5β-reductase
in infants, children and adolescents aged 1 month to 18 years and adults.
Exclusively for healthcare professionals, Orphabase is an educational website and patient surveillance database that is part of Orphacol’s risk management plan® http://orphabase-login.icta.fr
This medicinal product is subject to additional monitoring.

Neofordex ®

Dexamethasone

  • Previously called Neodex® (when it had a Temporary Utilisation Authorisation)
  • Tablet containing 40 mg dexamethasone in packs of 10
In adults for the treatment of symptomatic multiple myeloma

For product information

If you would like more information on any of the products marketed by CTRS via our medical information service, click here.

To report adverse reaction

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in a product leaflet.
By reporting side effects, you can help provide more information about the safety of a medicine.
If you wish to report an adverse reaction, contact the Pharmacovigilance service by clicking here.

You can also report side effects directly through your country’s national reporting system. For this, you can refer to the product’s information leaflet.

For any other question, you can write to us directly using the contact form.